212 related articles for article (PubMed ID: 34418488)
1. TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
Yildirim M; Yildirim TC; Turay N; Bildik T; Ibibik B; Evcili I; Ersan PG; Tokat UM; Sahin O; Gursel I
Immunol Lett; 2021 Nov; 239():32-41. PubMed ID: 34418488
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
3. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Chaput N; Schartz NE; André F; Taïeb J; Novault S; Bonnaventure P; Aubert N; Bernard J; Lemonnier F; Merad M; Adema G; Adams M; Ferrantini M; Carpentier AF; Escudier B; Tursz T; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2137-46. PubMed ID: 14764679
[TBL] [Abstract][Full Text] [Related]
4. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.
Morishita M; Takahashi Y; Matsumoto A; Nishikawa M; Takakura Y
Biomaterials; 2016 Dec; 111():55-65. PubMed ID: 27723556
[TBL] [Abstract][Full Text] [Related]
5. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade.
Zhang Y; Lin A; Sui Q; Zhang C; Tian Z; Zhang J
Cancer Lett; 2014 Dec; 355(1):76-84. PubMed ID: 25224571
[TBL] [Abstract][Full Text] [Related]
6. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
7. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
8. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
9. Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response.
Kocabas BB; Almacioglu K; Bulut EA; Gucluler G; Tincer G; Bayik D; Gursel M; Gursel I
J Control Release; 2020 Dec; 328():587-595. PubMed ID: 32971199
[TBL] [Abstract][Full Text] [Related]
10. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
[TBL] [Abstract][Full Text] [Related]
11. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
[TBL] [Abstract][Full Text] [Related]
12. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
13. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
[TBL] [Abstract][Full Text] [Related]
14. Leishmanial CpG DNA nanovesicles: A propitious prophylactic approach against visceral leishmaniasis.
Tiwari RK; Chandrakar P; Gupta CL; Sayyed U; Shekh R; Bajpai P
Int Immunopharmacol; 2021 Jan; 90():107181. PubMed ID: 33249044
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
16. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
17. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
18. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.
Damo M; Wilson DS; Simeoni E; Hubbell JA
Sci Rep; 2015 Dec; 5():17622. PubMed ID: 26631690
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
20. Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.
Goodwin TJ; Huang L
Vaccine; 2017 May; 35(19):2550-2557. PubMed ID: 28385609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
